Evidence map›Paper›PMID 40766126›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Metabolic factors associated with plasma phosphorylated tau analytes used to detect Alzheimer's disease pathology.

Kao Lee Yang, Yue Ma, Gilda Ennis, Erin Jonaitis, Ramiro Eduardo Rea Reyes, Sterling C Johnson, Nicholas J Ashton, Kaj Blennow, Henrik Zetterberg, Barbara B Bendlin

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Kao Lee YangWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Yue MaWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Gilda EnnisWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Erin JonaitisWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Ramiro Eduardo Rea ReyesWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Sterling C JohnsonWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Nicholas J AshtonDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Henrik ZetterbergWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.
Barbara B BendlinWisconsin Alzheimer's Disease Research Center, University of Wisconsin, Madison, WI.

Funding

The Neighborhoods Study: Contextual Disadvantage and Alzheimer’s Disease and Related Dementias (ADRD)R01AG070883 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI AMY J. KIND · 2021 to 2026
$42.1M
Wisconsin Registry for Alzheimer's Prevention: Sex Differences in DNA MethylationR01AG027161 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Nathaniel Ark Chin, Sterling C Johnson · 2007 to 2026
$35.6M
Wisconsin Alzheimer's Disease Research CenterP30AG062715 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Henrik Zetterberg · 2019 to 2026
$34.5M
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALSUL1RR025011 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$29.5M
Wisconsin Alzheimer's Disease Research CenterP50AG033514 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI SAGER, MARK · 2009 to 2018
$16.2M
African Americans Fighting Alzheimer’s in Midlife (AA-FAIM)R01AG054059 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI CAREY E GLEASON · 2016 to 2026
$15.3M
White matter degeneration: biomarkers in preclinical Alzheimer's DiseaseR01AG037639 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA · 2012 to 2023
$5.3M
SV2A PET imaging in Alzheimer's DiseaseR01AG062285 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, CHRISTIAN, BRADLEY T · 2018 to 2022
$5.3M
Gut barrier function in Alzheimer's DiseaseR01AG070973 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, REY, FEDERICO E · 2021 to 2025
$3.9M
Neighborhood Socioeconomic Contextual Disadvantage and Alzheimer's DiseaseRF1AG057784 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, KIND, AMY J. · 2017 to 2017
$3.8M
Algebraic Formulations for Characterizing Structural Brain Connectivity Changes and Pathology Transmission Networks in Preclinical Alzheimer's DiseaseRF1AG059312 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI BENDLIN, BARBARA BRIGITTA, SINGH, VIKAS · 2019 to 2019
$1.8M
A multimodal examination of Alzheimer's disease pathology and synaptic lossF31AG087651 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI Kao Lee Yang · 2025 to 2026
$82k
NCRR NIH HHS UL1 RR025011NIA NIH HHS F31 AG087651NIA NIH HHS P30 AG062715NIA NIH HHS P50 AG033514NIA NIH HHS R01 AG027161NIA NIH HHS R01 AG037639NIA NIH HHS R01 AG054059NIA NIH HHS R01 AG062285NIA NIH HHS R01 AG070883NIA NIH HHS R01 AG070973NIA NIH HHS RF1 AG057784NIA NIH HHS RF1 AG059312
6 · The paper itself

Abstract

introductionThe interpretation of plasma phosphorylated tau (pTau) levels may be influenced by metabolic conditions, such as insulin resistance (IR), type 2 diabetes mellitus (T2DM), obesity, and kidney function. We examined the extent to which metabolic factors are associated with plasma pTau concentrations (pTau181, pTau217, pTau231) and the contribution of these factors on analytical outcomes.

methodsWe analyzed data from 287 participants using partial Spearman's rho, Mann Whitney U, ROC analysis, and linear mixed models.

resultsConcordance between plasma pTau217 and amyloid PET was not influenced by IR or estimated-glomerular-filtration-rate (eGFR). Accounting for eGFR improved concordance of pTau181 and pTau231 with amyloid PET. Age, binarized waist-to-hip ratio, and amyloid status were associated with all longitudinal pTau concentrations, and eGFR associated with longitudinal pTau231. DISCUSSION: Metabolic health may influence the interpretation of some plasma pTau biomarkers, potentially necessitating adjustments for metabolic factors in research and clinical settings.

Identifiers

PMID40766126
PMCPMC12324621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.